vs
Tecnoglass Inc.（TGLS）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Tecnoglass Inc.的季度营收约是再鼎医药的1.9倍（$245.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs 2.4%），Tecnoglass Inc.自由现金流更多（$11.4M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 12.8%）
Tecnoglass Inc.是一家领先的建筑玻璃、铝制门窗及相关建材生产商，主要服务北美及拉美地区的住宅和商业建筑领域，为新建及翻新项目提供定制化、高能效的建筑解决方案。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
TGLS vs ZLAB — 直观对比
营收规模更大
TGLS
是对方的1.9倍
$127.1M
营收增速更快
ZLAB
高出14.7%
2.4%
自由现金流更多
TGLS
多$38.1M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
12.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $245.3M | $127.1M |
| 净利润 | $26.1M | — |
| 毛利率 | 40.0% | 51.0% |
| 营业利润率 | 18.3% | -54.6% |
| 净利率 | 10.6% | — |
| 营收同比 | 2.4% | 17.1% |
| 净利润同比 | -44.5% | — |
| 每股收益（稀释后） | $0.57 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TGLSZLAB
| Q4 25 | $245.3M | $127.1M | ||
| Q3 25 | $260.5M | $115.4M | ||
| Q2 25 | $255.5M | $109.1M | ||
| Q1 25 | $222.3M | $105.7M | ||
| Q4 24 | $239.6M | $108.5M | ||
| Q3 24 | $238.3M | $101.8M | ||
| Q2 24 | $219.7M | $100.1M | ||
| Q1 24 | $192.6M | $87.1M |
净利润TGLSZLAB
| Q4 25 | $26.1M | — | ||
| Q3 25 | $47.2M | $-36.0M | ||
| Q2 25 | $44.1M | $-40.7M | ||
| Q1 25 | $42.2M | $-48.4M | ||
| Q4 24 | $47.0M | — | ||
| Q3 24 | $49.5M | $-41.7M | ||
| Q2 24 | $35.0M | $-80.3M | ||
| Q1 24 | $29.7M | $-53.5M |
毛利率TGLSZLAB
| Q4 25 | 40.0% | 51.0% | ||
| Q3 25 | 42.7% | 59.5% | ||
| Q2 25 | 44.7% | 60.6% | ||
| Q1 25 | 43.9% | 63.6% | ||
| Q4 24 | 44.5% | 61.5% | ||
| Q3 24 | 45.8% | 64.1% | ||
| Q2 24 | 40.8% | 64.9% | ||
| Q1 24 | 38.8% | 61.4% |
营业利润率TGLSZLAB
| Q4 25 | 18.3% | -54.6% | ||
| Q3 25 | 25.1% | -42.3% | ||
| Q2 25 | 24.0% | -50.3% | ||
| Q1 25 | 26.7% | -53.3% | ||
| Q4 24 | 28.0% | -62.6% | ||
| Q3 24 | 28.4% | -66.6% | ||
| Q2 24 | 23.3% | -76.0% | ||
| Q1 24 | 21.3% | -80.7% |
净利率TGLSZLAB
| Q4 25 | 10.6% | — | ||
| Q3 25 | 18.1% | -31.2% | ||
| Q2 25 | 17.3% | -37.3% | ||
| Q1 25 | 19.0% | -45.8% | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 20.8% | -40.9% | ||
| Q2 24 | 15.9% | -80.2% | ||
| Q1 24 | 15.4% | -61.4% |
每股收益（稀释后）TGLSZLAB
| Q4 25 | $0.57 | $-0.05 | ||
| Q3 25 | $1.01 | $-0.03 | ||
| Q2 25 | $0.94 | $-0.04 | ||
| Q1 25 | $0.90 | $-0.04 | ||
| Q4 24 | $1.00 | $-0.09 | ||
| Q3 24 | $1.05 | $-0.04 | ||
| Q2 24 | $0.75 | $-0.08 | ||
| Q1 24 | $0.63 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $104.1M | $689.6M |
| 总债务越低越好 | $174.4M | — |
| 股东权益账面价值 | $713.1M | $715.5M |
| 总资产 | $1.3B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.24× | — |
8季度趋势，按日历期对齐
现金及短期投资TGLSZLAB
| Q4 25 | $104.1M | $689.6M | ||
| Q3 25 | $127.1M | $717.2M | ||
| Q2 25 | $140.9M | $732.2M | ||
| Q1 25 | $160.2M | $757.3M | ||
| Q4 24 | $137.5M | $779.7M | ||
| Q3 24 | $124.8M | $616.1M | ||
| Q2 24 | $129.5M | $630.0M | ||
| Q1 24 | $138.8M | $650.8M |
总债务TGLSZLAB
| Q4 25 | $174.4M | — | ||
| Q3 25 | $114.7M | — | ||
| Q2 25 | $110.6M | — | ||
| Q1 25 | $110.6M | — | ||
| Q4 24 | $111.1M | — | ||
| Q3 24 | $126.8M | — | ||
| Q2 24 | $144.7M | — | ||
| Q1 24 | $160.9M | — |
股东权益TGLSZLAB
| Q4 25 | $713.1M | $715.5M | ||
| Q3 25 | $764.0M | $759.9M | ||
| Q2 25 | $736.0M | $791.7M | ||
| Q1 25 | $685.1M | $810.8M | ||
| Q4 24 | $631.2M | $840.9M | ||
| Q3 24 | $613.3M | $667.7M | ||
| Q2 24 | $574.8M | $704.2M | ||
| Q1 24 | $573.6M | $762.2M |
总资产TGLSZLAB
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $1.2B | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $996.3M | $985.3M | ||
| Q2 24 | $942.5M | $987.4M | ||
| Q1 24 | $981.6M | $988.4M |
负债/权益比TGLSZLAB
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 0.15× | — | ||
| Q1 25 | 0.16× | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | 0.21× | — | ||
| Q2 24 | 0.25× | — | ||
| Q1 24 | 0.28× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $31.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $11.4M | $-26.7M |
| 自由现金流率自由现金流/营收 | 4.7% | -21.0% |
| 资本支出强度资本支出/营收 | 8.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.19× | — |
| 过去12个月自由现金流最近4个季度 | $34.5M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流TGLSZLAB
| Q4 25 | $31.0M | $-26.0M | ||
| Q3 25 | $40.0M | $-32.0M | ||
| Q2 25 | $17.9M | $-31.0M | ||
| Q1 25 | $46.9M | $-61.7M | ||
| Q4 24 | $61.1M | $-55.8M | ||
| Q3 24 | $41.5M | $-26.8M | ||
| Q2 24 | $34.5M | $-42.2M | ||
| Q1 24 | $33.4M | $-90.1M |
自由现金流TGLSZLAB
| Q4 25 | $11.4M | $-26.7M | ||
| Q3 25 | $21.2M | $-35.0M | ||
| Q2 25 | $-14.7M | $-33.9M | ||
| Q1 25 | $16.5M | $-63.2M | ||
| Q4 24 | $35.4M | $-58.4M | ||
| Q3 24 | $17.8M | $-28.2M | ||
| Q2 24 | $14.2M | $-42.9M | ||
| Q1 24 | $23.6M | $-91.1M |
自由现金流率TGLSZLAB
| Q4 25 | 4.7% | -21.0% | ||
| Q3 25 | 8.2% | -30.4% | ||
| Q2 25 | -5.7% | -31.1% | ||
| Q1 25 | 7.4% | -59.9% | ||
| Q4 24 | 14.8% | -53.8% | ||
| Q3 24 | 7.5% | -27.7% | ||
| Q2 24 | 6.5% | -42.9% | ||
| Q1 24 | 12.2% | -104.5% |
资本支出强度TGLSZLAB
| Q4 25 | 8.0% | 0.5% | ||
| Q3 25 | 7.2% | 2.6% | ||
| Q2 25 | 12.7% | 2.6% | ||
| Q1 25 | 13.7% | 1.5% | ||
| Q4 24 | 10.7% | 2.4% | ||
| Q3 24 | 9.9% | 1.3% | ||
| Q2 24 | 9.2% | 0.7% | ||
| Q1 24 | 5.1% | 1.1% |
现金转化率TGLSZLAB
| Q4 25 | 1.19× | — | ||
| Q3 25 | 0.85× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 1.11× | — | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.98× | — | ||
| Q1 24 | 1.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
